AR044009A1 - PHARMACEUTICAL COMBINATION INCLUDING ELETRIPTAN AND SODIUM BICARBONATE - Google Patents

PHARMACEUTICAL COMBINATION INCLUDING ELETRIPTAN AND SODIUM BICARBONATE

Info

Publication number
AR044009A1
AR044009A1 ARP040101192A ARP040101192A AR044009A1 AR 044009 A1 AR044009 A1 AR 044009A1 AR P040101192 A ARP040101192 A AR P040101192A AR P040101192 A ARP040101192 A AR P040101192A AR 044009 A1 AR044009 A1 AR 044009A1
Authority
AR
Argentina
Prior art keywords
sodium bicarbonate
eletriptan
pharmaceutical combination
combination including
prevention
Prior art date
Application number
ARP040101192A
Other languages
Spanish (es)
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0308469A external-priority patent/GB0308469D0/en
Priority claimed from GB0312479A external-priority patent/GB0312479D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of AR044009A1 publication Critical patent/AR044009A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Combinación de a) eletriptan, o una de sus sales farmacéuticamente aceptables, y b) bicarbonato de sodio. La combinación proporciona una absorción rápida de eletriptan cuando se toma por vía oral. La combinación es útil para el tratamiento o la prevención de una enfermedad para la que es indicado un agente agonista de 5-HT1, particularmente en el tratamiento de una migraña o para la prevención de una recurrencia de migraña. Composición farmacéutica, uso y método de tratamiento o prevención.Combination of a) eletriptan, or a pharmaceutically acceptable salt thereof, and b) sodium bicarbonate. The combination provides rapid absorption of eletriptan when taken orally. The combination is useful for the treatment or prevention of a disease for which a 5-HT1 agonist agent is indicated, particularly in the treatment of a migraine or for the prevention of a migraine recurrence. Pharmaceutical composition, use and method of treatment or prevention.

ARP040101192A 2003-04-11 2004-04-07 PHARMACEUTICAL COMBINATION INCLUDING ELETRIPTAN AND SODIUM BICARBONATE AR044009A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0308469A GB0308469D0 (en) 2003-04-11 2003-04-11 Pharmaceutical combination
GB0312479A GB0312479D0 (en) 2003-05-30 2003-05-30 Pharmaceutical combination

Publications (1)

Publication Number Publication Date
AR044009A1 true AR044009A1 (en) 2005-08-24

Family

ID=33161221

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040101192A AR044009A1 (en) 2003-04-11 2004-04-07 PHARMACEUTICAL COMBINATION INCLUDING ELETRIPTAN AND SODIUM BICARBONATE

Country Status (12)

Country Link
EP (1) EP1615635A1 (en)
JP (1) JP2006522790A (en)
AR (1) AR044009A1 (en)
BR (1) BRPI0409127A (en)
CA (1) CA2521902A1 (en)
MX (1) MXPA05010070A (en)
NL (1) NL1025908C2 (en)
PA (1) PA8599901A1 (en)
PE (1) PE20050086A1 (en)
TW (1) TW200423929A (en)
UY (1) UY28260A1 (en)
WO (1) WO2004089365A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009142771A2 (en) * 2008-05-22 2009-11-26 Plus Chemicals, S.A. Salts of (r)-5-(2-phenylsulphonylethenyl)-3-(n- methylpyrrolidin-2-ylmethyl)-1h-indole, 5-bromo-3-[(r)-1- methyl-pyrrolidin-2- ylmethyl]-1h-indole and of eletriptan
IT1393700B1 (en) 2009-04-22 2012-05-08 F S I Fabbrica Italiana Sint SYNTHESIS OF 3 - {[(2R) -1-METHYLPYROLIDIN-2-IL] METHYL} -5- [2- (PHENILSULFONYL) ETYL] -1H-INDOL
JP6878021B2 (en) * 2016-02-02 2021-05-26 第一三共ヘルスケア株式会社 Pharmaceutical composition containing triptan and ascorbic acid
CR20210061A (en) * 2018-07-03 2021-03-18 Axsome Therapeutics Inc PHARMACEUTICAL COMPOSITIONS INCLUDING MELOXICAM
MY198967A (en) * 2019-02-06 2023-10-05 Axsome Therapeutics Inc Pharmaceutical compositions comprising meloxicam

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1197038B (en) * 1986-08-01 1988-11-25 Zambon Spa PHARMACEUTICAL COMPOSITION WITH ANALGESIC ACTIVITY
US5607951A (en) 1990-10-15 1997-03-04 Pfizer Inc Indole derivatives
IT1272149B (en) * 1993-03-26 1997-06-11 Zambon Spa PHARMECEUTICAL COMPOSITION WITH ANALGESIC ACTIVITY
GB9417310D0 (en) 1994-08-27 1994-10-19 Pfizer Ltd Therapeutic agents
US6488961B1 (en) 1996-09-20 2002-12-03 Ethypharm, Inc. Effervescent granules and methods for their preparation
GB9704524D0 (en) * 1997-03-05 1997-04-23 Smithkline Beecham Plc Composition
GB9816556D0 (en) 1998-07-30 1998-09-30 Pfizer Ltd Therapy
GB9825988D0 (en) 1998-11-27 1999-01-20 Pfizer Ltd Indole derivatives
CO5261541A1 (en) * 1999-05-14 2003-03-31 Pfizer Prod Inc COMBINATION THERAPY FOR THE TREATMENT OF MIGRANA
GB0018968D0 (en) 2000-08-02 2000-09-20 Pfizer Ltd Particulate composition
GB0105131D0 (en) * 2001-03-01 2001-04-18 Pfizer Ltd Compositions having improved bioavailability
GB0129117D0 (en) * 2001-12-05 2002-01-23 Glaxo Group Ltd Pharmaceutical composition
EP1594470A4 (en) * 2003-02-19 2007-10-17 Biovail Lab Int Srl Rapid absorption selective 5-ht agonist formulations

Also Published As

Publication number Publication date
WO2004089365A1 (en) 2004-10-21
NL1025908C2 (en) 2005-11-22
BRPI0409127A (en) 2006-03-28
CA2521902A1 (en) 2004-10-21
PA8599901A1 (en) 2005-02-04
PE20050086A1 (en) 2005-03-01
NL1025908A1 (en) 2004-10-13
TW200423929A (en) 2004-11-16
MXPA05010070A (en) 2005-11-23
JP2006522790A (en) 2006-10-05
EP1615635A1 (en) 2006-01-18
UY28260A1 (en) 2004-11-30

Similar Documents

Publication Publication Date Title
CL2004000643A1 (en) PHARMACEUTICAL COMPOSITION INCLUDING A 5-HT 1B / 1D AGONIST AND A SELECTIVE CYCLLOXYGENASA-2 INHIBITOR, USEFUL IN THE TREATMENT OF MIGRANE.
BRPI0408396A (en) orally consumable, rapidly dissolving films containing pharmaceutically active agents
UY28285A1 (en) CONSUMABLE FILES BY ORAL ROUTE THAT DISSOLVES QUICKLY, CONTAINING A SWEETENER
PA8502901A1 (en) TREATMENT OF COMBINATION WITH IL-1RA AND COMPOUNDS THAT INHIBIT THE PROCESSING AND RELEASE OF IL-1
CY1109119T1 (en) PHARMACEUTICAL FORMS OF LONG-TERM RELEASE INCLUDING LAMOTRIGIN
CL2004000931A1 (en) CONSUMABLE FILM ADAPTED TO ADHER AND DISSOLVE IN THE ORAL CAVITY THAT INCLUDES A MODIFIED ALMIDON AND A PHARMACEUTICALLY ACTIVE AGENT.
AR062860A1 (en) THERAPEUTIC COMBINATIONS 482
CY1116693T1 (en) A combination of azelastin and cycloneside
CY1108725T1 (en) Combination of NMDA antagonist and acetylcholinesterase inhibitors for the treatment of ALZHEIMER
PA8484301A1 (en) PHARMACEUTICAL FORMULATIONS OF CONTROLLED LIBERATION
CY1110130T1 (en) MORPHOLINE PRODUCTS FOR USE AS DOPAMINE AGONISTS IN THERAPEUTIC DISEASE Therapeutic Treatment I.A.
GT200500309A (en) DERIVATIVES OF SULFONILBENCILIMIDAZOL
BRPI0414558A (en) pharmaceutical composition comprising a p2x7 receptor antagonist and a non-steroidal anti-inflammatory drug
UY28007A1 (en) THERAPEUTIC TREATMENT
CO5540294A2 (en) A COMBINATION OF A RAPAMYCIN DERIVATIVE AND A SELECTED RENTING AGENT OF CYCLPHOSPHAMIDE AND CARMUSTINE AND COMPOSITIONS CONTAINING THEM
AR044453A1 (en) METOXI-PIRAZIN-TIENIL SULFONAMIDE DERIVATIVES
AR041595A1 (en) THERAPEUTIC TREATMENT
UY28260A1 (en) PHARMACEUTICAL COMBINATION
UY27679A1 (en) AMBROXOL FOR THE TREATMENT OF PAINFUL STATES IN THE ORAL AND FARINGIAN CAVITY.
AR032422A1 (en) USE OF IL-18 INHIBITORS FOR THE TREATMENT AND / OR PREVENTION OF CARDIAC DISEASE
AR038858A1 (en) COMBINATION
AR024232A1 (en) ELETRIPTAN MONOHIDRATADO BROMHYDRATE, PHARMACEUTICAL COMPOSITION, ITS USE IN THE PREPARATION OF MEDICINES AND PROCEDURE FOR THEIR PREPARATION
AR038305A1 (en) ORGANALLY DISPERSABLE PHARMACEUTICAL COMPOSITION OF PERINDOPRIL
MXPA03001833A (en) Treatment of urinary dysfunction.
DK1575362T3 (en) Use of an acaricide powder

Legal Events

Date Code Title Description
FB Suspension of granting procedure